Our recent projects involve the design and execution of tracking studies in the cardio-renal space, specifically for the hyperphosphatemia and hyperkalemia markets.
In these markets many new products are now being introduced by both large and small pharma and biotech companies. Most of these companies also have additional products already on the market or in the pipeline.
The hyperphosphatemia and hyperkalemia markets provide excellent examples of an environment that is not only multi-layered in its structure, but one which demands precision in the development of appropriate study content. The execution, fieldwork, and the extraction of the study’s data must hold a standard of accuracy and precision to reflect the highly complex and challenging research outcomes.
We carve out the insights, marketing understanding, and accurate and reliable forecasts by asking the right questions according to our clients’ needs.
Consider phosphate binder use:
- Do patients and their healthcare providers share the same view about daily use?
- Exactly what real-life experiences result from daily use, and
- How/to what extent do those experiences impact market needs?
Drawing out reliable answers to such questions in a tracking study requires very specialized expertise, particularly when utilizing large-scale surveys, as we do in this case with CKD patients and their HCPs.
To ask the right questions, it is imperative to have a high level of familiarity with the current market and its players as well as the expertise to phrase the questions in a direct, clear, and understandable way. This holds true especially when conducting tracking surveys online, as we do.
In our “trackers”, we also actively incorporate qualitative study elements which help capture the emotional responses behind patient and prescriber experiences. It is possible to accurately measure and strategically target the emotions and feelings that explain unmet needs or that drive an individual to certain actions. These measurements are among the most critical metrics, not only in assessing product satisfaction, but also in driving growth and profitability. In our market niche of hyperphosphatemia / hyperkalemia, measuring emotions about drugs or patient-physician interactions becomes even more critical.
The quality of a tracking survey rises or falls with the quality of the study sample. The reliability and composition of a tracking study must accurately represent reality. We incorporate smart and logic-based study standards with a mix of detailed screening, logic, and consistency checks, as well as “control” questions that confirm true users and prescribers of the drugs.
PPP/ PS combine the viewpoints of both patients and physicians and then compare them to actual statistics to ensure that the studies are relevant.
An interview must have a logical flow and also maintain the interest of participants. This is accomplished through its contents and by presenting the questions in a way that keeps respondents engaged and alert. Interview lengths do not exceed 20-25 minutes minutes.
We adapt the frequency of our hyperphosphatemia and hyperkalemia “trackers” to the variable rate at which perspectives have been known to change. Our tracking studies are executed on a biannual basis at minimum.
What do we mean by “top level data analytics”?
Our hyperphosphatemia and hyperkalemia tracker reports are called “PROfilers”. Analytics takes place in-house, adding precision to valuation and forecasting purposes by connecting facts and insights of HCP and patient perspectives and delivering related guidance on how to use our data.
We have conducted extensive research into the cardiorenal market with our PROfilers in the United States and Europe. We are excited to announce that we are now expanding our research into the Japanese market.
We offer our clients the opportunity to participate in customized studies, semi-customized (adding questions pertaining to their specific needs to our existing research), or fully syndicated.
Contact us if you want to know more about our hyperkalemia and hyperphosphatemia PROfilers.